Renaissance Capital logo

Contineum Therapeutics Priced, Nasdaq: CTNM

Phase 1 biotech developing small molecule therapies for inflammatory diseases.

Industry: Health Care

Latest Trade: $15.91 0.00 (0.0%)

First Day Return: -3.8%

Return from IPO: -0.6%

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications with high unmet need. We have focused our efforts on developing selective compounds targeting challenging molecular pathways, and through these efforts, have built a portfolio of small molecule drug candidates. Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). LPA1R antagonism is a clinically validated mechanism, and we believe that our preclinical studies and Phase 1 healthy volunteer data support the continued development of PIPE-791 for both IPF and Progressive MS. Specifically, based on its high bioavailability, low plasma protein binding, and long receptor residence time in our preclinical studies compared to the preclinical data of other LPA1 antagonists that we know are currently in development, we also believe PIPE-791 has the potential to be a differentiated LPA1R therapy.
more less
IPO Data
IPO File Date 03/15/2024
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.9
Deal Size ($mm) $110
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/04/2024
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.9
Deal Size ($mm) $110
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
Morgan Stanley
more
Company Data
Headquarters San Diego, CA, United States
Founded 2017
Employees 31
Website www.pipelinetherapeutics.com

Contineum Therapeutics (CTNM) Performance